Christopher J. H. Porter

27.5k total citations · 8 hit papers
311 papers, 21.7k citations indexed

About

Christopher J. H. Porter is a scholar working on Pharmaceutical Science, Oncology and Molecular Biology. According to data from OpenAlex, Christopher J. H. Porter has authored 311 papers receiving a total of 21.7k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Pharmaceutical Science, 98 papers in Oncology and 90 papers in Molecular Biology. Recurrent topics in Christopher J. H. Porter's work include Drug Solubulity and Delivery Systems (86 papers), Drug Transport and Resistance Mechanisms (76 papers) and Advanced Drug Delivery Systems (34 papers). Christopher J. H. Porter is often cited by papers focused on Drug Solubulity and Delivery Systems (86 papers), Drug Transport and Resistance Mechanisms (76 papers) and Advanced Drug Delivery Systems (34 papers). Christopher J. H. Porter collaborates with scholars based in Australia, United States and United Kingdom. Christopher J. H. Porter's co-authors include William N. Charman, Natalie L. Trevaskis, Colin W. Pouton, Ben J. Boyd, Lisa M. Kaminskas, Susan A. Charman, Hywel D. Williams, Glenn A. Edwards, Ann Marie Kaukonen and Hassan Benameur and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Christopher J. H. Porter

307 papers receiving 21.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs

2007 1.4k citations Christopher J. H. Porter, Natalie L. Trevaskis et al. profile →
Strategies to Address Low Drug Solubility in Discovery and Development

2013 1.3k citations Hywel D. Williams, Natalie L. Trevaskis et al. Pharmacological Reviews profile →
Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies

2007 685 citations Colin W. Pouton, Christopher J. H. Porter profile →
Enhancing intestinal drug solubilisation using lipid-based delivery systems

2007 580 citations Christopher J. H. Porter, Colin W. Pouton et al. profile →
From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity

2015 517 citations Natalie L. Trevaskis, Lisa M. Kaminskas et al. profile →
Minimum information reporting in bio–nano experimental literature

2018 482 citations Matthew Faria, Mattias Björnmalm et al. Nature Nanotechnology profile →
Physicochemical and Physiological Mechanisms for the Effects of Food on Drug Absorption: The Role of Lipids and pH

1997 480 citations Christopher J. H. Porter et al. Journal of Pharmaceutical Sciences profile →
50 years of oral lipid-based formulations: Provenance, progress and future perspectives

2016 340 citations Orlagh M. Feeney, Claire L. McEvoy et al. profile →

Peers

Countries citing papers authored by Christopher J. H. Porter

Since Specialization

Citations

This map shows the geographic impact of Christopher J. H. Porter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher J. H. Porter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher J. H. Porter more than expected).

Fields of papers citing papers by Christopher J. H. Porter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher J. H. Porter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher J. H. Porter. The network helps show where Christopher J. H. Porter may publish in the future.

Co-authorship network of co-authors of Christopher J. H. Porter

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher J. H. Porter. A scholar is included among the top collaborators of Christopher J. H. Porter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher J. H. Porter. Christopher J. H. Porter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimizing Triglyceride Prodrugs of a Model Immunomodulator: Conjugation through the Phenol of Mycophenolic Acid (MPA) Markedly Promotes Lymphatic Drug Transport 2025 ·Molecular Pharmaceutics ·Luojuan Hu, Tim Quach, Dan Zheng, (unknown), Garima Sharma, (unknown), Daniel K. Bonner, Natalie L. Trevaskis, Jamie S. Simpson, Sifei Han, Christopher J. H. Porter	0
2	Lymphatic Uptake of a Highly Lipophilic Protease Inhibitor Prodrug from a Lipid-Based Formulation is Limited by Instability in the Intestine 2024 ·Journal of Pharmaceutical Sciences ·(unknown), (unknown), (unknown), (unknown), Anthony R.J. Phillips, John A. Windsor, Christopher J. H. Porter, Sifei Han, Natalie L. Trevaskis	0
3	Intestinal Lymphatic Biology, Drug Delivery, and Therapeutics: Current Status and Future Directions 2024 ·Pharmacological Reviews ·(unknown), (unknown), Mohammad Abdallah, Sifei Han, Luojuan Hu, Orlagh M. Feeney, (unknown), (unknown), (unknown), Muhammad Asim Farooq, (unknown), Anthony R.J. Phillips, John A. Windsor, Christopher J. H. Porter, Enyuan Cao, Natalie L. Trevaskis	1
4	Increasing Linker Chain Length and Intestinal Stability Enhances Lymphatic Transport and Lymph Node Exposure of Triglyceride Mimetic Prodrugs of a Model Immunomodulator Mycophenolic Acid 2023 ·Molecular Pharmaceutics ·Sifei Han, Tim Quach, Luojuan Hu, (unknown), Dan Zheng, (unknown), Garima Sharma, Daniel K. Bonner, Jamie S. Simpson, Natalie L. Trevaskis, Christopher J. H. Porter	4
5	Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability 2021 ·Molecular Pharmaceutics ·Yusuke Tanaka, Tri‐Hung Nguyen, Estelle J. A. Suys, Christopher J. H. Porter	9
6	A lipid-anchored neurokinin 1 receptor antagonist prolongs pain relief by a three-pronged mechanism of action targeting the receptor at the plasma membrane and in endosomes 2021 ·Journal of Biological Chemistry ·N. Quynh, Priyank A. Shenoy, Tim Quach, Jeffri S. Retamal, Arisbel B. Gondin, Holly R. Yeatman, Luigi Aurelio, (unknown), Daniel P. Poole, Meritxell Canals, Cameron J. Nowell, Bim Graham, Thomas P. Davis, Stephen J. Briddon, Stephen J. Hill, Christopher J. H. Porter, Nigel W. Bunnett, Michelle L. Halls, Nicholas A. Veldhuis	15
7	Molecular Dynamics Simulations and Experimental Results Provide Insight into Clinical Performance Differences between Sandimmune® and Neoral® Lipid-Based Formulations 2021 ·Pharmaceutical Research ·Dallas B. Warren, (unknown), (unknown), Karen Corbett, (unknown), Leigh Ford, Hywel D. Williams, Vincent Jannin, Hassan Benameur, Christopher J. H. Porter, David K. Chalmers, Colin W. Pouton	6
8	High-Density Lipoprotein Composition Influences Lymphatic Transport after Subcutaneous Administration 2020 ·Molecular Pharmaceutics ·(unknown), Enyuan Cao, Orlagh M. Feeney, Angus P. R. Johnston, Christopher J. H. Porter, Natalie L. Trevaskis	25
9	Lymphatic Uptake of Liposomes after Intraperitoneal Administration Primarily Occurs via the Diaphragmatic Lymphatics and is Dependent on Liposome Surface Properties 2019 ·Molecular Pharmaceutics ·Given Lee, Sifei Han, (unknown), Enyuan Cao, Jiwon Hong, Anthony R.J. Phillips, John A. Windsor, Christopher J. H. Porter, Natalie L. Trevaskis	34
10	A ligand-induced structural change in fatty acid–binding protein 1 is associated with potentiation of peroxisome proliferator–activated receptor α agonists 2019 ·Journal of Biological Chemistry ·Rahul Patil, Biswaranjan Mohanty, (unknown), Indu R. Chandrashekaran, Stephen J. Headey, M.L. Williams, Craig S. Clements, (unknown), B.C. Doak, (unknown), Richard Weaver, Laurent Vuillard, Michelle L. Halls, Christopher J. H. Porter, M.J. Scanlon	19
11	Engineering Biocoatings To Prolong Drug Release from Supraparticles 2019 ·Biomacromolecules ·Yutian Ma, Christina Cortez‐Jugo, Jianhua Li, Zhixing Lin, Rachael T. Richardson, Yiyuan Han, Jiajing Zhou, Mattias Björnmalm, Orlagh M. Feeney, Qi‐Zhi Zhong, Christopher J. H. Porter, Andrew K. Wise, Frank Caruso	27
12	Minimum information reporting in bio–nano experimental literature breakdown → 2018 ·Nature Nanotechnology ·Matthew Faria, Mattias Björnmalm, Kristofer J. Thurecht, Stephen J. Kent, Robert G. Parton, Maria Kavallaris, Angus P. R. Johnston, J. Justin Gooding, Simon R. Corrie, Ben J. Boyd, Pall Thordarson, Andrew K. Whittaker, Molly M. Stevens, Clive A. Prestidge, Christopher J. H. Porter, Wolfgang J. Parak, Thomas P. Davis, Edmund J. Crampin, Frank Caruso	482
13	Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations 2018 ·Molecular Pharmaceutics ·Hywel D. Williams, Leigh Ford, Sifei Han, (unknown), (unknown), David M. Shackleford, D. Vodak, Hassan Benameur, Colin W. Pouton, Peter J. Scammells, Christopher J. H. Porter	46
14	Gel-Mediated Electrospray Assembly of Silica Supraparticles for Sustained Drug Delivery 2018 ·ACS Applied Materials & Interfaces ·Yutian Ma, Mattias Björnmalm, Andrew K. Wise, Christina Cortez‐Jugo, Eve Revalor, Yi Ju, Orlagh M. Feeney, Rachael T. Richardson, Eric Hanssen, Robert K. Shepherd, Christopher J. H. Porter, Frank Caruso	42
15	Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies 2017 ·Molecular Pharmaceutics ·(unknown), Tri‐Hung Nguyen, Leigh Ford, Claire L. McEvoy, Hywel D. Williams, Peter J. Scammells, Christopher J. H. Porter	51
16	Computational Models of the Intestinal Environment. 3. The Impact of Cholesterol Content and pH on Mixed Micelle Colloids 2017 ·Molecular Pharmaceutics ·Estelle J. A. Suys, Dallas B. Warren, Christopher J. H. Porter, Hassan Benameur, Colin W. Pouton, David K. Chalmers	25
17	Glyceride‐Mimetic Prodrugs Incorporating Self‐Immolative Spacers Promote Lymphatic Transport, Avoid First‐Pass Metabolism, and Enhance Oral Bioavailability 2016 ·Angewandte Chemie International Edition ·Luojuan Hu, Tim Quach, Sifei Han, (unknown), (unknown), Danielle Senyschyn, Natalie L. Trevaskis, Jamie S. Simpson, Christopher J. H. Porter	55
18	Glyceride‐Mimetic Prodrugs Incorporating Self‐Immolative Spacers Promote Lymphatic Transport, Avoid First‐Pass Metabolism, and Enhance Oral Bioavailability 2016 ·Angewandte Chemie ·Luojuan Hu, Tim Quach, Sifei Han, (unknown), (unknown), Danielle Senyschyn, Natalie L. Trevaskis, Jamie S. Simpson, Christopher J. H. Porter	7
19	An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity 2008 ·Journal of Pharmacy and Pharmacology ·Kasiram Katneni, Susan A. Charman, Christopher J. H. Porter	17
20	Cationic Poly- l -lysine Dendrimers: Pharmacokinetics, Biodistribution, and Evidence for Metabolism and Bioresorption after Intravenous Administration to Rats 2006 ·Molecular Pharmaceutics ·Ben J. Boyd, Lisa M. Kaminskas, Peter Karellas, Guy Y. Krippner, (unknown), Christopher J. H. Porter	118

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact